• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Phase Forward Sees 22% Jump in Revenues

Phase Forward Sees 22% Jump in Revenues

February 6, 2007
CenterWatch Staff

Waltham, Mass.-based eClinical company Phase Forward reported a 22% jump in revenues to $106.6 million in 2006, compared with the previous year’s $87.1 million. In the fourth quarter of 2006, the company posted revenues of $30.2 million, a 28% increase compared with the fourth quarter of 2005.

Income from operations was $4.1 million, representing an increase of 67% from the prior year period and an operating margin of 13.6%. Income from operations was $13.2 million in 2006, representing an increase of 46% from 2005 and a full year operating margin of 12.4%. Net income was $16.2 million, or $0.45 per diluted share, for the full year compared with $12.7 million, or $0.36 per diluted share in 2005. Phase Forward’s share price jumped 7% to $14.49 on Feb. 1.

The company also won a contract with the Dublin-based CRO ICON. The agreement will be under Phase Forward’s CRO Advantage Program. ICON secured four studies in the fourth quarter that will use Phase Forward’s EDC solution, InForm. Phase Forward stated it added 38 new clients in 2006, including CardioFocus, Altana Pharma AG (now part of Nycomed)  Teijin Pharma and Orexigen.

“The fourth quarter was a strong finish to an excellent year for Phase Forward. During 2006, we accomplished key objectives such as winning numerous major purchase decisions, expanding and diversifying our customer base, and enhancing our market leadership position,” said Bob Weiler, chief executive officer for the firm.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing